about
Dendritic Cell Therapy in an Allogeneic-Hematopoietic Cell Transplantation Setting: An Effective Strategy toward Better Disease Control?Will post-transplantation cell therapies for pediatric patients become standard of care?Antitumor immune responses mediated by dendritic cells: How signals derived from dying cancer cells drive antigen cross-presentationRoute of administration of the TLR9 agonist CpG critically determines the efficacy of cancer immunotherapy in mice.Differential Toll-like receptor recognition and induction of cytokine profile by Bifidobacterium breve and Lactobacillus strains of probiotics.Cognate CD4 T-cell licensing of dendritic cells heralds anti-cytomegalovirus CD8 T-cell immunity after human allogeneic umbilical cord blood transplantationPlatinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and miceChemical-specific properties co-determine the type of adverse immune response.Generation of a cord blood-derived Wilms Tumor 1 dendritic cell vaccine for AML patients treated with allogeneic cord blood transplantation.Dendritic cells: tools and targets for antitumor vaccination.Efficient loading of dendritic cells following cryo and radiofrequency ablation in combination with immune modulation induces anti-tumour immunity.Harnessing dendritic cells for tumor antigen presentationToll-like receptor signalling on Tregs: to suppress or not to suppress?An Ocular Protein Triad Can Classify Four Complex Retinal Diseases.Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy?Natural killer cells facilitate PRAME-specific T-cell reactivity against neuroblastoma.Immune Reconstitution after Allogeneic Hematopoietic Cell Transplantation in Children.Challenges in the harmonization of immune monitoring studies and trial design for cell-based therapies in the context of hematopoietic cell transplantation for pediatric cancer patients.Human neonatal thymectomy induces altered B-cell responses and auto-reactivity.Immune reconstitution and outcomes after conditioning with anti-thymocyte-globulin in unrelated cord blood transplantation; the good, the bad, and the ugly.Moving toward endotypes in atopic dermatitis: Identification of patient clusters based on serum biomarker analysis.Strategies before, during, and after hematopoietic cell transplantation to improve T-cell immune reconstitution.Association between anti-thymocyte globulin exposure and survival outcomes in adult unrelated haemopoietic cell transplantation: a multicentre, retrospective, pharmacodynamic cohort analysis.Migration of dendritic cells to the lymph nodes and its enhancement to drive anti-tumor responses.Microbial Dysbiosis in Common Variable Immune Deficiencies: Evidence, Causes, and Consequences.A transplantable TH-MYCN transgenic tumor model in C57Bl/6 mice for preclinical immunological studies in neuroblastoma.Immune adjuvant efficacy of CpG oligonucleotide in cancer treatment is founded specifically upon TLR9 function in plasmacytoid dendritic cells.Selective expansion of merocytic dendritic cells and CD8DCs confers anti-tumour effect of Fms-like tyrosine kinase 3-ligand treatment in vivo.Phenotypic variability in patients with ADA2 deficiency due to identical homozygous R169Q mutations.In vivo colocalization of antigen and CpG [corrected] within dendritic cells is associated with the efficacy of cancer immunotherapy.Viral reactivations and associated outcomes in the context of immune reconstitution after pediatric hematopoietic cell transplantation.Antigen-specific IgA titres after 23-valent pneumococcal vaccine indicate transient antibody deficiency disease in children.Interleukin-21 receptor-mediated signals control autoreactive T cell infiltration in pancreatic islets.Generation of antibody responses to pneumococcal capsular polysaccharides is independent of CD1 expression in mice.Increased prevalence of gastrointestinal viruses and diminished secretory immunoglobulin a levels in antibody deficiencies.Antigen cross-presentation by dendritic cell subsets: one general or all sergeants?Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors.Selective requirement for CD40-CD154 in drug-induced type 1 versus type 2 responses to trinitrophenyl-ovalbumin.TLR ligands in the local treatment of established intracerebral murine gliomas.Anti-inflammatory and immune regulatory properties of 5-androsten-3beta, 17beta-diol (HE2100), and synthetic analogue HE3204: implications for treatment of autoimmune diseases.
P50
Q26830857-12E91400-B482-4198-9F47-8B1005921A81Q27008318-5D8145EA-F931-4BBF-AF5D-6BBB9008B443Q27026193-49D032D3-A491-43F2-9637-3E6887BD4E16Q33519555-B646878C-0BBA-483C-9B06-54DDC66359C1Q34626740-236C30B1-E696-4A14-8397-1FEC33E4F31AQ34991001-A30F6D61-6588-4374-BCA9-6AB0EF190D61Q35142813-AB4EF34A-0837-4280-9F15-25A31B5D05EBQ35172024-F26D286E-0A82-482D-B176-FB5B868B149CQ36107961-99A22C21-4EDE-4665-9DD9-94D176F25428Q36284556-9B0576A7-E826-4E24-9224-1542E767C104Q36611772-5E7E3D66-4C47-4A37-A350-FFB9C4731A6BQ37132747-6C092928-9DA2-4E41-A2CD-47E262C97591Q37186819-5AF0C790-A1EB-45D8-B601-3AD3B912E2DBQ37609515-8A5C7574-B884-4725-98F0-52B3512D3187Q37973820-0676B98B-56F9-47CD-82F6-B5D7801FA517Q38262786-39B7C880-DCA1-4541-A12F-0E74E2415B10Q38581051-B284A13D-0FC1-43E3-8212-8A86A5FBF9D1Q38641112-F9839E9C-7C2D-4AAF-BFCA-2FF49CAB3964Q38686764-466B4483-B409-493C-818E-4B8042165635Q38728525-C79DF7E0-85DF-48EE-B27A-6A1C2126CB67Q38730017-8DCA0A95-BBB6-4624-8EE9-33E1618C4BEEQ38815206-5B47E7F9-0BE2-4AFC-A09B-E1EDCC8A4B06Q38885564-E779503B-80EF-4F6B-92E9-0E3E6C4B030BQ39002527-E5ADAA00-C970-4BE7-9727-4283768DF226Q39054216-84143A04-6020-45F6-8135-86EFF7463058Q39095788-C2196E61-1A2A-4191-A652-5FCE8A07CC2AQ39501063-83C44184-241C-4521-933C-6263169B63D2Q39607848-B03E31C9-7EF4-4C35-A778-621A1D07050AQ40004227-CD602E7C-1F46-40D9-8F0E-DDAF44079201Q40075292-B3E84E4F-8A43-467B-AC68-79AE2226EE2FQ40251404-88A91527-2A38-47B3-9ED7-AEA6616F50BBQ40492302-04A8CE2F-6E4C-49D9-9B28-1B0BC78E86D9Q41887106-A0A07631-2023-4A12-8A3C-80BF92522E3BQ42025073-7345B231-A575-407A-8F6B-64D1499EABBBQ42199205-70119408-C7E8-4539-B993-AD9908FA2DAFQ42245307-3E295EDB-9388-4DAF-8322-65D0D21998A5Q42554303-1CB03CC9-AF1B-4738-ADD4-493EFFAF3E29Q43950653-C7B2AE91-D1CD-4D93-ACE5-C177562B0BF6Q44062204-8066F6BC-4F5B-49DC-A4FE-6520990BBE34Q44625703-3665CABC-D47B-4036-BC43-7DD6D74D49E8
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Stefan Nierkens
@ast
Stefan Nierkens
@en
Stefan Nierkens
@es
Stefan Nierkens
@nl
Stefan Nierkens
@sl
type
label
Stefan Nierkens
@ast
Stefan Nierkens
@en
Stefan Nierkens
@es
Stefan Nierkens
@nl
Stefan Nierkens
@sl
prefLabel
Stefan Nierkens
@ast
Stefan Nierkens
@en
Stefan Nierkens
@es
Stefan Nierkens
@nl
Stefan Nierkens
@sl
P106
P21
P31
P496
0000-0003-3406-817X